FDA Grants Accelerated Approval to Elafibranor (Iqirvo) for PBC

The accelerated approval is based on data from the phase 3 ELATIVE trial demonstrating a reduction in alkaline phosphatase with elafibranor.

Related Keywords

Italy ,United Kingdom ,Milan ,Lombardia ,Washington ,United States ,Kris Kowdley ,Christelle Huguet ,Ipsen Iqirvo ,Liver Institute ,Healthcare Products Regulatory Authority ,Drug Administration ,European Medicines Agency ,American Association ,Liver Disease ,Liver Institute Northwest ,European Association ,United Kingdom Medicines ,Healthcare Products Regulatory ,Breakthrough Therapy Designation ,New Drug Application ,Prescription Drug User Fee Act ,New England Journal ,Elafibranor Slows Disease Progression ,Improves Itch Related Qol ,